Terumo establishes a group-wide “DE&I philosophy” to further cultivate a diverse, equitable and inclusive culture
TOKYO, Feb. 28, 2022 /PRNewswire/ — Terumo Corporation (TSE: 4543) today announced that it has implemented a global “DE&I Philosophy” to further cultivate the culture of diversity, equity and inclusion ( DE&I) within the Terumo group. Additionally, a “DE&I Guiding Principle” has also been defined to embed the DE&I Standards of Behavior into policies, processes and day-to-day work practices.
Terumo provides medical products and solutions in more than 160 countries and regions. Currently, approximately 70% of the company’s revenue is generated outside of its head office in Japan*1and of the 26,000 Terumo Group associates around the world, nearly 80% work outside of Japan*2. Terumo believes it is very important for associates to respect and value differences as well as to empower everyone to bring their authentic selves to work, in order to spark the innovation that will drive the company’s continued growth. business.
To create the DE&I Philosophy and the DE&I Guiding Principle, associates from diverse backgrounds in terms of nationality, work and generation formed a “DE&I Global Council”. The DE&I philosophy and the The DE&I Guiding Principles are aligned with Terumo’s Core Values and the Terumo Group Code of Conduct and clearly articulate the commitment to cultivating a globally diverse, equitable and inclusive culture.
Additionally, to celebrate and appreciate DE&I in the workplace, a “Terumo DE&I Week” will be held for all associates worldwide. This year, various activities will be held from March 7 to 11; such as video messages from the management team, an online DE&I roundtable, as well as local events in each company of the Group.
In April 2022, Terumo will launch the first year of its 5-year growth strategy (GS26). The new strategy also highlights the need to create an inclusive work environment. With the DE&I philosophy in place, Terumo will strive harder to fulfill the company’s goal of advancing healthcare and improving the quality of life for patients.
*1 Revenue for the 2020 financial year (April 2020 for March 2021): 613.8 billion yen / Japan: 201.8 billion yen / Apart from Japan: 412.0 billion yen
*2 Distribution of partners by region: Japan 23.4% / Americas 42.8% / EMEA 8.8% / China 6.6% / APAC 18.4% (at March 2021)
Terumo is committed to cultivating a globally diverse, equitable and inclusive culture
DE&I Guiding Principle
At Terumo, we respect and value differences, and empower everyone to bring their authentic selves to work, leading to innovation that meets the diverse health needs of global society.
To promote diversity, equity and inclusion (DE&I):
- We are committed to living our Core Values and Code of Conduct.
- We embed DE&I into our policies, processes and practices.
- We do not tolerate words or actions that diminish DE&I such as discrimination, violence or hatred.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “contributing to society through healthcare” for nearly 100 years. Situated at Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to deliver innovative medical solutions in more than 160 countries and regions. The company started as a Japanese manufacturer of thermometers and has been supporting healthcare ever since. Today, its extensive business portfolio ranges from vascular interventions and cardio-surgical solutions, blood transfusion and cell therapy technologies, to medical products essential to daily clinical practice such as transfusion systems, diabetes care and peritoneal dialysis treatments. Terumo will also strive to be useful to patients, healthcare professionals and society as a whole.